Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06657209
PHASE4

Normal-weight Diabetes: Adipocyte-directed Therapy with Pioglitazone or Tirzepatide

Sponsor: Stanford University

View on ClinicalTrials.gov

Summary

This study is to investigate how adipocyte (fat cell) function and fat distribution differ between individuals with normal-weight type 2 diabetes (NWD) and normal-weight controls without diabetes (NWC). The study will assess whether adipocyte-directed therapies, specifically pioglitazone and tirzepatide, can improve insulin resistance, adipocyte function, and fat distribution in individuals with NWD. By analyzing the biological mechanisms underlying adipocyte dysfunction, the study aims to provide insights into novel treatment strategies for improving metabolic health in normal-weight individuals with type 2 diabetes.

Key Details

Gender

All

Age Range

30 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

104

Start Date

2024-12-15

Completion Date

2027-12-15

Last Updated

2024-10-24

Healthy Volunteers

Yes

Interventions

PROCEDURE

Insulin resistance testing

Steady state Plasma Glucose test

PROCEDURE

OGTT

Will collect 5 blood draws during the test to measure insulin secretion

PROCEDURE

Fat biopsy

Needle biopsy to gather a sample of abdominal subcutaneous fat

RADIATION

DXA scan

Whole body DXA scan

PROCEDURE

MRI

Abdominal MRI

PROCEDURE

1H-MRS

Spectroscopy of the abdominal region

DRUG

Tirzepatide

16 weeks started at 2.5mg/week and increased to 5mg/week dose

DRUG

Pioglitazone

16 weeks at a 45mg/day dose

Locations (1)

Stanford University, Clinical and Translational Research Unit (CTRU)

Stanford, California, United States